Vectura has entered into a global development and licence agreement with Janssen Biotech for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD.
The collaboration will focus initially on the development of a Phase II candidate and has the potential to include additional clinical-stage candidates.
Searching for more deal information? Current Partnering offers the following options:
|
The collaboration will leverage Vectura’s expertise and proprietary dry powder inhaler technologies in the development of inhaled therapeutics.
Vectura will apply its delivery technologies to develop Janssen’s pulmonary products into late-stage clinical development and commercialisation.
Janssen will lead the clinical development programmes, with Vectura taking responsibility for pharmaceutical development and preparation for Phase II clinical trials.
The deal comprises upfront and development milestones and a tiered royalty on net sales. Financial terms of the agreement are not disclosed.
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
